📊 RLMD Key Takeaways
Is Relmada Therapeutics, Inc.. (RLMD) a Good Investment?
Relmada is a pre-commercial biotech company with emerging revenue ($5.2M) but catastrophic financial fundamentals: -$227.8M free cash flow burn, only $3.5M cash reserves, and $59.1M operating losses. With current burn rates, cash runway is measured in weeks without additional financing, creating severe dilution risk and viability concerns.
Relmada shows severe and persistent unprofitability with near-zero gross margin, deeply negative operating income, and heavy cash burn despite headline revenue growth. With minimal cash relative to burn and no debt capacity to lean on, fundamentals point to financing/dilution risk unless margins and operating efficiency improve materially.
Why Buy Relmada Therapeutics, Inc.. Stock? RLMD Key Strengths
- Revenue growing 93.7% YoY indicates emerging commercial traction
- Zero debt (Debt/Equity 0.00x) provides capital structure flexibility
- Stockholders' equity of $86.5M provides asset backing
- Debt-free capital structure (0.00x D/E)
- High reported liquidity (Current/Quick >14x)
- Revenue up 93.7% YoY (albeit small base)
RLMD Stock Risks: Relmada Therapeutics, Inc.. Investment Risks
- Free cash flow of -$227.8M annually with only $3.5M cash creates critical runway crisis (weeks at current burn)
- Operating loss of $59.1M vs. $5.2M revenue shows no visible path to profitability or cash flow breakeven
- Capital expenditures of $182.1M indicate ongoing significant cash demands; no evidence of funded development pipeline
- Sustained large operating losses and -1100%+ margins
- Severely negative free cash flow and limited cash runway
- Gross margin ~0%, raising concerns about revenue quality/sustainability
Key Metrics to Watch
- Monthly cash burn rate and months of runway remaining
- Clinical trial milestones, FDA approvals, and revenue-driving achievements
- Success in raising capital or reaching revenue inflection points
- Operating cash flow (burn rate)
- Cash and equivalents (including short-term investments)
Relmada Therapeutics, Inc.. (RLMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.62x current ratio provides a solid financial cushion.
RLMD Profit Margin, ROE & Profitability Analysis
RLMD vs Healthcare Sector: How Relmada Therapeutics, Inc.. Compares
How Relmada Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Relmada Therapeutics, Inc.. Stock Overvalued? RLMD Valuation Analysis 2026
Based on fundamental analysis, Relmada Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Relmada Therapeutics, Inc.. Balance Sheet: RLMD Debt, Cash & Liquidity
RLMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Relmada Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.65 indicates the company is currently unprofitable.
RLMD Revenue Growth, EPS Growth & YoY Performance
RLMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2014 | $682 | -$13.2K | N/A |
| Q1 2014 | $1.9K | -$9.0K | N/A |
| Q3 2013 | $400 | -$3.4K | N/A |
| Q2 2013 | $2.3K | -$942 | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Relmada Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
RLMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Relmada Therapeutics, Inc.. (CIK: 0001553643)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RLMD
What is the AI rating for RLMD?
Relmada Therapeutics, Inc.. (RLMD) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RLMD's key strengths?
Claude: Revenue growing 93.7% YoY indicates emerging commercial traction. Zero debt (Debt/Equity 0.00x) provides capital structure flexibility. ChatGPT: Debt-free capital structure (0.00x D/E). High reported liquidity (Current/Quick >14x).
What are the risks of investing in RLMD?
Claude: Free cash flow of -$227.8M annually with only $3.5M cash creates critical runway crisis (weeks at current burn). Operating loss of $59.1M vs. $5.2M revenue shows no visible path to profitability or cash flow breakeven. ChatGPT: Sustained large operating losses and -1100%+ margins. Severely negative free cash flow and limited cash runway.
What is RLMD's revenue and growth?
Relmada Therapeutics, Inc.. reported revenue of $5.2M.
Does RLMD pay dividends?
Relmada Therapeutics, Inc.. does not currently pay dividends.
Where can I find RLMD SEC filings?
Official SEC filings for Relmada Therapeutics, Inc.. (CIK: 0001553643) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RLMD's EPS?
Relmada Therapeutics, Inc.. has a diluted EPS of $-1.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RLMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Relmada Therapeutics, Inc.. has a STRONG SELL rating with 71% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RLMD stock overvalued or undervalued?
Valuation metrics for RLMD: ROE of -66.3% (sector avg: 15%), net margin of -1,113.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RLMD stock in 2026?
Our dual AI analysis gives Relmada Therapeutics, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RLMD's free cash flow?
Relmada Therapeutics, Inc..'s operating cash flow is $-45.8M, with capital expenditures of $182.1M. FCF margin is -4,422.6%.
How does RLMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,113.9% (avg: 12%), ROE -66.3% (avg: 15%), current ratio 14.62 (avg: 2).